Powder: -20°C for 3 years | In solvent: -80°C for 1 year
BFH772 是 VEGFR2抑制剂(IC50:3 nM),具有口服活性。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 269 | 现货 | ||
2 mg | ¥ 383 | 现货 | ||
5 mg | ¥ 618 | 现货 | ||
10 mg | ¥ 997 | 现货 | ||
25 mg | ¥ 1,980 | 现货 | ||
50 mg | ¥ 2,970 | 现货 | ||
100 mg | ¥ 4,590 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 693 | 现货 |
产品描述 | BFH772, a structure analogue of BAW2881, is a potent and selective VEGF inhibitor. BFH772 is highly effective at targeting VEGFR2 kinase with an IC50 value of 3 nM. BFH772 inhibits the ligand induced autophosphorylation of RET, PDGFR, and KIT kinases, with IC50 values ranging between 30 and 160 nM. |
靶点活性 | VEGFR2:3 nM |
体外活性 | 每天口服3 mg/kgBFH772有效地抑制黑色素瘤的生长(原发性肿瘤减少54-90%;转移瘤减少71-96%). |
体内活性 | BFH772抑制配体所诱导的RET、PDGFR、KIT激酶的自磷酸化,IC50为30-160 nM。BFH772有效地靶向VEGFR2,IC50为3 nM。而对FLK-1、FLT-1、FLT-4的有效性比对VEGFR2低500倍。除了VEGFR2,它还能靶向B-RAF,RET和TIE-2,尽管对它们的有效性比对VEGFR2低40倍以上。 |
激酶实验 | In vitro kinase assay is based on a filter binding assay, using the recombinant GST-fused kinase domains expressed in baculovirus and purified over glutathione-sepharose, γ-[33P]ATP as the phosphate donor, and poly(Glu:Tyr 4:1) peptide as the acceptor. Each GST-fused kinase is incubated under optimized buffer conditions [20 mM Tris-HCl buffer (pH 7.5), 1-3 mM MnCl2, 3-10 mM MgCl2, 3-8 μg/mL poly(Glu:Tyr 4:1), 0.25 mg/mL polyethylene glycol 20000, 8 μM ATP, 10 μM sodium vanadate, 1 mM DTT] and 0.2 μCi γ-33P ATP in a total volume of 30 μL in the presence or absence of a test substance for 10 min at ambient temperature. The reaction is stopped by adding 10 mL of 250 mM EDTA. Using a 384-well filter system, half the volume is transferred onto an Immobilon-polyvinylidene difluoride membrane. The membrane is then washed extensively and dried, and scintillation counting is performed. IC50s for compounds are calculated by linear regression analysis of the percentage inhibition[1]. |
细胞实验 | Subconfluent HUVECs were incubated in triplicate in 96-well plates with basal medium containing 1.5% FCS and a constant concentration of VEGF (10 ng/mL), bFGF (0.5 ng/mL), or FCS (5%) in the presence or absence of compounds. After 24 h of incubation, BrdUrd labeling solution was added and cells incubated an additional 24 h before fixation, blocking, and addition of peroxidaselabeled anti-BrdUrd antibody. Bound antibody was then detected spectrophotometrically at 450 nm.(Only for Reference) |
别名 | BFH-722 |
分子量 | 439.39 |
分子式 | C23H16F3N3O3 |
CAS No. | 890128-81-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: 81 mg/mL (184.3 mM)
H2O: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 81 mg/mL (184.3 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
Ethanol / DMSO | 1 mM | 2.2759 mL | 11.3794 mL | 22.7588 mL | 56.8971 mL |
5 mM | 0.4552 mL | 2.2759 mL | 4.5518 mL | 11.3794 mL | |
10 mM | 0.2276 mL | 1.1379 mL | 2.2759 mL | 5.6897 mL | |
20 mM | 0.1138 mL | 0.569 mL | 1.1379 mL | 2.8449 mL | |
50 mM | 0.0455 mL | 0.2276 mL | 0.4552 mL | 1.1379 mL | |
100 mM | 0.0228 mL | 0.1138 mL | 0.2276 mL | 0.569 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
BFH772 890128-81-1 Angiogenesis Tyrosine Kinase/Adaptors VEGFR BFH-772 inhibit BFH-722 BFH 722 Vascular endothelial growth factor receptor Inhibitor BFH722 BFH 772 inhibitor